Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HPV8-E6 drives coordinated transcriptional and epigenetic reprogramming of keratinocytes.

Tumour virus research·2026
Same author

Urologic outcomes in children with closed spinal dysraphism with and without untethering of the spinal cord.

Journal of pediatric surgery·2026
Same author

Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation.

Exploration of neuroscience·2025
Same author

Pediatric-Type Diffuse Low-Grade Gliomas with <i>MYB</i> Alterations: Neuroimaging of the Diffuse Astrocytomas, <i>MYB-</i> or <i>MYBL1</i>-Altered.

AJNR. American journal of neuroradiology·2025
Same author

Genome sequencing reveals CCDC88A variants in malformations of cortical development and immune dysfunction.

Human molecular genetics·2025
Same author

Stable excess mortality in a multiple sclerosis cohort diagnosed 1970-2010.

European journal of neurology·2024

Related Experiment Video

Updated: Jan 2, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.4K

Progressive Multifocal Leukoencephalopathy: Current Insights.

Marge Kartau1, Jussi Ot Sipilä2,3,4, Eeva Auvinen5

  • 1Clinical Neurosciences, Neurology, Helsinki University Hospital and Helsinki University, Helsinki, Finland.

Degenerative Neurological and Neuromuscular Disease
|December 11, 2019
PubMed
Summary

Progressive multifocal leukoencephalopathy (PML) risk varies by patient subgroup, including those with hematological malignancies, HIV, or monoclonal antibody treatments. Restoring immune function is key for PML treatment, and better risk assessment tools are needed.

Keywords:
HIVJC polyomavirusdisease modifying therapiesmonoclonal antibodiesmultiple sclerosisprogressive multifocal leukoencephalopathy

More Related Videos

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

4.6K
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.5K

Related Experiment Videos

Last Updated: Jan 2, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.4K
A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

4.6K
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.5K

Area of Science:

  • Neuroimmunology
  • Infectious Diseases
  • Oncology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic demyelinating disease of the central nervous system.
  • Predisposing factors significantly influence PML incidence, clinical course, and prognosis.
  • Key at-risk groups include patients with hematological malignancies, HIV infection, and those treated with monoclonal antibodies (mAbs).

Purpose of the Study:

  • To review the current understanding of PML risk factors and epidemiological shifts.
  • To highlight the importance of immune reconstitution as the primary treatment strategy for PML.
  • To identify the need for improved risk stratification and prevention strategies for PML.

Main Methods:

  • Review of existing epidemiological data and clinical literature on PML.
  • Analysis of risk factors associated with different patient subgroups.
  • Evaluation of current and potential treatment approaches for PML.

Main Results:

  • The distribution of PML risk groups appears to be changing, with evolving epidemiological data.
  • Restoration of immune function is the most effective treatment for PML, though no specific anti-JCPyV therapy exists.
  • Systematic data collection and risk stratification algorithms are lacking, except for natalizumab (NTZ)-treated multiple sclerosis (MS) patients.

Conclusions:

  • PML cases require evaluation based on specific predisposing factors due to differing outcomes.
  • Further research into immune checkpoint inhibitors for specific PML subgroups is warranted.
  • Development of systematic registries and risk stratification tools is crucial for enhancing PML prevention and management.